ketoconazole has been researched along with Leukemia, Promyelocytic, Acute in 6 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Leukemia, Promyelocytic, Acute: An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, continuous oral dosing results in progressive decline in plasma drug concentrations, which is associated with relapse and resistance to this retinoid." | 2.67 | Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. ( DeGrazia, F; Francis, PA; Huselton, C; Kris, MG; Muindi, JR; Orazem, JP; Rigas, JR; Warrell, RP; Young, CW, 1993) |
| " Two potential ways of overcoming decreased plasma levels are suggested by the explanations for rapid elimination of ATRA: administration of a P-450 inhibitor such as ketoconazole to block oxidation of the drug, or use of an intermittent dosing schedule." | 2.39 | Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia. ( Adamson, PC, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamson, PC | 1 |
| Muindi, JR | 2 |
| Young, CW | 2 |
| Warrell, RP | 2 |
| Rigas, JR | 1 |
| Francis, PA | 1 |
| Kris, MG | 1 |
| Huselton, C | 1 |
| DeGrazia, F | 1 |
| Orazem, JP | 1 |
| Takahashi, N | 1 |
| Breitman, TR | 1 |
| Hayes, ME | 2 |
| Bayley, D | 2 |
| Mawer, EB | 2 |
2 reviews available for ketoconazole and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia.
Topics: Animals; Clinical Trials as Topic; Drug Administration Schedule; Humans; Ketoconazole; Leukemia, Pro | 1994 |
Clinical pharmacology of all-trans retinoic acid.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Ketoconazole; Leukemia, Promyelocytic, Acute; Lung Neoplasms | 1994 |
1 trial available for ketoconazole and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug | 1993 |
3 other studies available for ketoconazole and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
Covalent modification of proteins by ligands of steroid hormone receptors.
Topics: Calcitriol; Dinoprostone; Electrophoresis, Gel, Two-Dimensional; Electrophoresis, Polyacrylamide Gel | 1992 |
Studies on an adherent variant of the human promyelomonocytic HL60 leukaemia cell line that constitutively expresses 25-hydroxyvitamin D3-24-hydroxylase activity which is inhibited by 1 alpha,25-dihydroxyvitamin D3.
Topics: Calcitriol; Cell Adhesion; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; | 1991 |
Metabolism of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 and its sensitivity to ketoconazole in 1 alpha,25-dihydroxyvitamin D3-differentiated HL60 cells.
Topics: 24,25-Dihydroxyvitamin D 3; Calcifediol; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Differe | 1989 |